ENTITY
Chugai Pharmaceutical

Chugai Pharmaceutical (4519 JT)

13
Analysis
Health Care • Japan
Chugai Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals products. The Company develops drugs in the fields of cancer, infectious diseases, bone, blood, and circulatory systems. Chugai Pharmaceutical also conducts research studies on drugs with private and public medical research institutions globally.
more
•08 Nov 2018 16:30

Japan: Relative Price Score Update - Overbought and Oversold Sectors & Peer Groups

RELATIVE PRICE SCORE - The Relative Price Score (RPS) was introduced in an earlier insight and is a measure of stock price performance relative to...

Logo
605 Views
Share
•04 Nov 2018 17:10

Japan Fortnightly Update: Lower Low as Earnings Slow

LOWER LOW - Japanese equities reached a new 52-week low on 29th October but rebounded on the subsequent four trading days to close the...

Logo
639 Views
Share
•31 Oct 2018 10:14

Japan: The Demise of The "J Nifty-Fifty"?

THE J 'NIFTY-FIFTY' - In our insight posted on July 1st Japan: Most Overbought & Most Oversold - The Relative Price Score, we highlighted the...

Logo
658 Views
Share
•24 Oct 2018 23:03

Chugai 3Q FY18 (YE Dec'18) Results - First Glance

Key highlights Continued brisk export of Actemra (+10.8% to ¥19.5b) and Alecensa (+95.7% to ¥9.2b) to Roche drove Chugai’s 3Q FY18e sales (+4.8% to...

•09 Oct 2018 13:41

As Expected, USFDA Approves Hemlibra for Hemophilia A in Patients Without Inhibitors

Non-inhibitor patients constitute ~80-90% of the total hemophilia A population size Consequently, Hemlibra’s (emicizumab, in-house, US Launch -Nov...

x